HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allylix secures $6 mil. in venture capital

This article was originally published in The Rose Sheet

Executive Summary

San Diego, Calif.-based biotech firm has raised $6 mil. in Series C financing to commercialize grapefruit-derived nootkatone and other products for food and fragrance applications. Funding validates Allylix's technology platform - which "enables low-cost production of high-value terpene products through yeast fermentation" - and commercial viability, says CEO Carolyn Fritz. Nootkatone is currently produced through grapefruit peel extractions, creating a "long-lasting" citrus flavor used in fruit juices and sodas. Allylix plans to implement a more cost-efficient production process and expand applications of nootkatone to a broader range of products, including fragrances and pharmaceuticals, according to its Web site. Allylix says it expects another Series C financing round to be completed in 60 days

You may also be interested in...

P&G Teams With Firm To Turn Microbes Into Functional Ingredient "Factories"

Procter & Gamble and Emeryville, Calif.-based Amyris Inc. have entered into a collaborative agreement to leverage the biotech firm's genetically engineered yeast in the development of personal-care ingredients

Tech Companies Grappling With A Brave New World Of Regulations While Developing Digital-Health Products

Software firms interested in the digital-health arena are engaging US FDA more and bolstering their regulatory credentials to navigate an unfamiliar regulatory landscape, industry experts tell Medtech Insight.

Biosimilars: US FDA Considering ‘Guardrails’ To Prevent Misinformation

Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts